Elixir Medical Announces Schedule of Programs for TCT 2012

Three Year Follow-Up Data for the DESyne Novolimus Eluting Coronary Eluting Stent System, and One Year Follow-Up Data for the DESolve Bioresorbable Coronary Scaffold System to be Presented

SUNNYVALE, Calif.--(BUSINESS WIRE)--Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced that it will release three-year clinical follow-up data on its CE Mark-approved DESyne^® Novolimus Eluting Coronary Stent System, and one year clinical and MSCT (Multi Slice Computed Tomography) results for its fully bioresorbable drug-eluting scaffold system, the DESolve™ Bioresorbable Coronary Scaffold, at the 24^th annual Transcatheter Cardiovascular Technologies Conference in Miami on Tuesday, October 23.

Elixir will also announce new data on its other drug eluting stent platforms during the conference. Following are the details of Elixir Medical’s programs and activities at TCT in Eastern Standard Time (EST):

Tuesday, Oct. 23:

12 – 12:10 pm, Miami Beach Convention Center, Room C221/222

Session: Bioresorbable Vascular Scaffolds

6-Month Angiographic Follow-up of the Novel DESolve™ Myolimus-Eluting Bioresorbable Coronary Scaffold for the Treatment of Non-Complex Coronary Lesions – Results from the DESolve I First-In-Man Trial

• Ricardo Costa, MD, PhD, Institute of Dante Pazzanese de Cardiologia in Sao Paulo, Brazil

1:35 - 1:45 pm, Miami Beach Convention Center, Room B217/218

Session: First in Human Studies: Global Regulatory and Translational Considerations

Evaluation of the Myolimus-Eluting Bioresorbable Coronary Scaffold: 6-Month Clinical and Imaging Results

• Stefan Verheye, MD, PhD, ZNA Middleheim Hospital, Antwerp, Belgium

2:44 – 2:50 pm, Miami Beach Convention Center, Hall A – Coronary Theater

Session II: Metallic Drug-Eluting Stents with Bioabsorbable Polymers

DESyne BD – Program update

• Ricardo Costa, MD, PhD, Institute of Dante Pazzanese de Cardiologia in Sao Paulo, Brazil

5:22 - 5:32 pm, Miami Beach Convention Center, Hall A – Coronary Theater

Session: Next-Generation DES and Bioabsorbable Scaffolds

First-in-Man Results with a Myolimus-Eluting Bioresorbable PLLA-based Vascular Scaffold (Elixir DESolve)

• Stefan Verheye, MD, PhD, ZNA Middleheim Hospital, Antwerp, Belgium

6:30 – 8:30 pm, Loews Miami Beach Hotel, Americana Ballroom, Salon 4

1601 Collins Ave., Miami Beach, FL 33130

Vascular Restoration

The Bioresorbable DESolve Scaffold Platform

Agenda

• Reception

• Elixir Medical Program Overview

• DESyne Clinical Data

- EXCELLA II 3-year follow-up data of the DESyne Novolimus Eluting Coronary Stent System

• DESyne BD Clinical Data

• DESolve Scaffold Clinical Data

- One Year Follow-Up Results of the DESolve Bioresorbable Coronary Scaffold System

• Discussion and Closing Remarks

Chairman

Martin B. Leon, MD, New York – Presbyterian Hospital / Columbia University Medical Center, New York, NY, USA

Faculty

• John Ormiston, MBChB, Mercy Angiographic Unit, Auckland, New Zealand

• Joachim Schofer, MD, Universitares Herz- und GefaBzentrum, Hamburg, Germany

• Stefan Verheye, MD, PhD, ZNA Middleheim Hospital, Antwerp, Belgium

• Bernhard Witzenbichler, MD, Charite – Campus Benjamin Franklin, Berlin, Germany

Space is limited: Please register in advance at www.tctconference.com/satelliteprograms

Wednesday, Oct. 24:

1:45 pm, Miami Beach Convention Center, Main Arena

LIVE CASE from Sao Paulo, Brazil

DESolve Nx 6-month Angiographic, IVUS and OCT follow-up

• Professor Alexandre Abizaid, M.D., Ph.D., of the Institute of Dante Pazzanese de Cardiologia in Sao Paulo, Brazil

Elixir Medical will have a booth at TCT: Booth 929, Exhibit Hall. The booth will be open Tuesday, October 23^rd, 12:00 pm to 5:00 pm, and Wednesday through Thursday, October 25^th – 26^th from 9:00 am to 5:00 pm.

About Elixir Medical

Elixir Medical Corporation, a privately held company headquartered in Sunnyvale, California, develops products that combine state-of-the-art medical devices with advanced pharmaceuticals to provide innovative treatment solutions to patients worldwide. The company's next-generation drug-eluting stent systems and bioresorbable coronary scaffold are designed to optimize localized drug delivery to provide safe and effective treatments for cardiovascular patients. For more information, visit www.elixirmedical.com